FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133668754> ?p ?o ?g. }

• W2133668754 endingPage "1222" @default.
• W2133668754 startingPage "1216" @default.
• W2133668754 abstract "<h3>Objectives</h3> To describe drug survival, disease activity and clinical response in patients with rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on prospectively registered observational data from the nationwide Danish DANBIO registry. <h3>Methods</h3> 150 Patients with RA treated with abatacept and 178 treated with tocilizumab were identified. Drug survival was investigated. Response data were available in 104 and 97 patients, respectively. Changes in 28-joint Disease Activity Score (DAS28) based on C-reactive protein (CRP) and European League Against Rheumatism (EULAR) response after 24 and 48 weeks were investigated. No direct comparison of drugs was made. <h3>Results</h3> Median (IQR) disease duration was 8.5 (3–14)/9 (3–12) years (abatacept/tocilizumab). 95%/93% of patients had previously received one or more tumour necrosis factor inhibitor (TNFi). After 48 weeks, 54%/64% of patients (abatacept/tocilizumab) maintained treatment. Among patients with available response data, DAS28 was 5.3 (4.7–6.1), 3.4 (2.7–4.9) and 3.3 (2.5–4.3) at baseline, weeks 24 and 48, respectively, in the abatacept group and 5.4 (4.7–6.2), 2.9 (2.3–4.0) and 2.5 (1.9–4.5) in the tocilizumab group. At weeks 24 and 48, the remission rates for abatacept/tocilizumab were 19%/39% and 26%/58%, respectively. EULAR good-or-moderate response rates were 70%/88% and 77%/84%, respectively. The decline in DAS28 variables over time appeared similar between drugs, except for CRP, which seemed to decline more rapidly among tocilizumab-treated patients. <h3>Conclusions</h3> In patients with RA (≥90% TNFi failures), a good-or-moderate EULAR response was achieved in ≥70% of patients treated with abatacept or tocilizumab for 24 weeks in routine care. Apparent declines in DAS28 variables over time were similar between drugs, except for the more rapid CRP decline among tocilizumab-treated patients, directly caused by interleukin 6 inhibition." @default.
• W2133668754 created "2016-06-24" @default.
• W2133668754 creator A5001732092 @default.
• W2133668754 creator A5009304025 @default.
• W2133668754 creator A5010403338 @default.
• W2133668754 creator A5043461202 @default.
• W2133668754 creator A5044189591 @default.
• W2133668754 creator A5051797698 @default.
• W2133668754 creator A5057994974 @default.
• W2133668754 creator A5063586848 @default.
• W2133668754 creator A5069336592 @default.
• W2133668754 creator A5072664936 @default.
• W2133668754 creator A5078386764 @default.
• W2133668754 creator A5080616680 @default.
• W2133668754 date "2011-05-08" @default.
• W2133668754 modified "2023-10-14" @default.
• W2133668754 title "Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry" @default.
• W2133668754 cites W1966874995 @default.
• W2133668754 cites W1979364075 @default.
• W2133668754 cites W1984842785 @default.
• W2133668754 cites W1993510043 @default.
• W2133668754 cites W2000905503 @default.
• W2133668754 cites W2014081699 @default.
• W2133668754 cites W2046628605 @default.
• W2133668754 cites W2069473482 @default.
• W2133668754 cites W2073831898 @default.
• W2133668754 cites W2079359234 @default.
• W2133668754 cites W2096862304 @default.
• W2133668754 cites W2097341637 @default.
• W2133668754 cites W2099888906 @default.
• W2133668754 cites W2100974168 @default.
• W2133668754 cites W2110177517 @default.
• W2133668754 cites W2110306625 @default.
• W2133668754 cites W2111034338 @default.
• W2133668754 cites W2113609304 @default.
• W2133668754 cites W2114308202 @default.
• W2133668754 cites W2116843833 @default.
• W2133668754 cites W2124670599 @default.
• W2133668754 cites W2125212735 @default.
• W2133668754 cites W2127532898 @default.
• W2133668754 cites W2139339400 @default.
• W2133668754 cites W2142625311 @default.
• W2133668754 cites W2150952126 @default.
• W2133668754 cites W2152348310 @default.
• W2133668754 cites W2157770246 @default.
• W2133668754 cites W2319957449 @default.
• W2133668754 cites W3146223861 @default.
• W2133668754 doi "https://doi.org/10.1136/ard.2010.140129" @default.
• W2133668754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21551512" @default.
• W2133668754 hasPublicationYear "2011" @default.
• W2133668754 type Work @default.
• W2133668754 sameAs 2133668754 @default.
• W2133668754 citedByCount "119" @default.
• W2133668754 countsByYear W21336687542012 @default.
• W2133668754 countsByYear W21336687542013 @default.
• W2133668754 countsByYear W21336687542014 @default.
• W2133668754 countsByYear W21336687542015 @default.
• W2133668754 countsByYear W21336687542016 @default.
• W2133668754 countsByYear W21336687542017 @default.
• W2133668754 countsByYear W21336687542018 @default.
• W2133668754 countsByYear W21336687542019 @default.
• W2133668754 countsByYear W21336687542020 @default.
• W2133668754 countsByYear W21336687542021 @default.
• W2133668754 countsByYear W21336687542022 @default.
• W2133668754 countsByYear W21336687542023 @default.
• W2133668754 crossrefType "journal-article" @default.
• W2133668754 hasAuthorship W2133668754A5001732092 @default.
• W2133668754 hasAuthorship W2133668754A5009304025 @default.
• W2133668754 hasAuthorship W2133668754A5010403338 @default.
• W2133668754 hasAuthorship W2133668754A5043461202 @default.
• W2133668754 hasAuthorship W2133668754A5044189591 @default.
• W2133668754 hasAuthorship W2133668754A5051797698 @default.
• W2133668754 hasAuthorship W2133668754A5057994974 @default.
• W2133668754 hasAuthorship W2133668754A5063586848 @default.
• W2133668754 hasAuthorship W2133668754A5069336592 @default.
• W2133668754 hasAuthorship W2133668754A5072664936 @default.
• W2133668754 hasAuthorship W2133668754A5078386764 @default.
• W2133668754 hasAuthorship W2133668754A5080616680 @default.
• W2133668754 hasConcept C126322002 @default.
• W2133668754 hasConcept C141071460 @default.
• W2133668754 hasConcept C2777178219 @default.
• W2133668754 hasConcept C2777489490 @default.
• W2133668754 hasConcept C2777575956 @default.
• W2133668754 hasConcept C2779338263 @default.
• W2133668754 hasConcept C2779605438 @default.
• W2133668754 hasConcept C2780653079 @default.
• W2133668754 hasConcept C71924100 @default.
• W2133668754 hasConceptScore W2133668754C126322002 @default.
• W2133668754 hasConceptScore W2133668754C141071460 @default.
• W2133668754 hasConceptScore W2133668754C2777178219 @default.
• W2133668754 hasConceptScore W2133668754C2777489490 @default.
• W2133668754 hasConceptScore W2133668754C2777575956 @default.
• W2133668754 hasConceptScore W2133668754C2779338263 @default.
• W2133668754 hasConceptScore W2133668754C2779605438 @default.
• W2133668754 hasConceptScore W2133668754C2780653079 @default.
• W2133668754 hasConceptScore W2133668754C71924100 @default.
• W2133668754 hasIssue "7" @default.
• W2133668754 hasLocation W21336687541 @default.

• next